Business Wire

CA-FAUNA

7.7.2021 15:02:05 CEST | Business Wire | Press release

Share
With Global Demand Growing, Fauna Launches New Region Groups, Achieves SOC 2 Compliance, and Adds Sales Leader to Further Accelerate Company Momentum

Fauna , the data API for modern applications, today announced the availability of a new US and European Region Groups and attainment of SOC 2 compliance to support the data residency and regulatory compliance needs of customers. The company also announced the addition of new sales leadership with deep developer and enterprise sales experience. The combination of these new features and sales leadership will help accelerate customer adoption of Fauna globally.

Thus far in 2021 Fauna has experienced 200+% growth in new customers in over 50 countries around the globe. Leveraging Fauna, these companies are bringing disruptive new applications to market more quickly by leaning heavily on the developer productivity that Fauna brings to the table, as well as by foregoing the need to care for and feed traditional database infrastructure.

“As our customer base has grown globally and larger organizations have begun adopting Fauna, it is critical for us to provide additional levels of compliance and more fine grained ways in which customers can manage their data residency needs within Fauna,” said Eric Berg, CEO of Fauna. “The combination of SOC2 compliance and our new Region Groups architecture allows us to meet those needs while still delivering a great developer experience and the zero database operations approach our customers love. Matt Slagle’s addition to the team to scale sales and build out a vibrant partner ecosystem also adds the right leadership and focus to accelerate our business by ensuring customers globally are successful with Fauna.”

New Geographic Region Groups

Unique to Fauna, its new Region Group capability allows global brands to meet local data residency requirements without compromising the performance, latency and reliability gained from distributing data across multiple cloud regions across a geography. Moreover, Region Groups control has been added to the zero operations experience that customers love about Fauna - no database operations required.

Countries around the world have introduced data sovereignty and privacy laws such as the GDPR that require companies to keep application data within the same area from which it was generated. However, to make applications more performant, and resilient, companies also want to bring data closer to their users across multiple cloud regions.

“App developers want to focus on building the app, not worrying about regional and international regulations and restrictions, or building high availability and redundancy services across modern distributed infrastructures,” said James Governor, co-founder of Redmonk. “Making control of data residency easy in specific geographical regions will make life much easier for developers.”

Fauna’s new capabilities address these requirements by enabling companies to pin their databases to a specific geographic area, called a Region Group. Within each Region Group, Fauna automatically distributes and scales these databases across multiple cloud regions within that area to minimize query latency while ensuring data resiliency. All of this is done without any operational overhead for a Fauna customer, continuing to deliver on our zero database operations promise.

Customers have the flexibility to mix and match Region Groups and create databases where the business demands. Developers can start locally within a single Region Group, and add new databases in additional geographic areas as their customer base grows globally.

“Fauna’s new Region Groups break new ground in how and where data is stored and scaled, which has a major impact on performance and data privacy,” said Hassen Karaa, Vice President of Product for Fauna. “We’ve put the right data infrastructure in place in each geographic region to meet our growing customer needs. Moreover, we manage it transparently so that our customers can focus on building applications that scale and comply with their data privacy local regulations and laws.”

SOC 2 Compliance

Data security, availability, confidentiality and reliability are critical considerations for businesses using public cloud infrastructure and SaaS vendors. As a cloud-native API Fauna was built with these in mind.

To demonstrate commitment to these principles Fauna chose the AICPA SOC2 framework of controls and is now SOC 2 Type 1 compliant. Fauna's service commitments and system requirements were achieved based on the trust services criteria relevant to security, availability, and confidentiality. A Type 1 report is available under NDA.

“As we continue to grow our services rapidly across the world, complying with local privacy regulations and data security is essential to our expansion, especially since we work with governments,” said Felix Engelhardt, Lead Engineer at EIDU. “Our use of Fauna has significantly accelerated our ability to bring ideas to market, and the new features being introduced today are critical to support our growth. We applaud Fauna’s innovation and responsiveness to our needs for compliance.”

New Sales Leadership to Drive Customer Success

As part of the company’s efforts to accelerate customer success, Fauna has hired Matt Slagle as its new Vice President of Sales. Slagle joins Fauna from New Relic, where he helped grow the company from less than 100 employees and under $10M in revenue to 2200 employees and ~$700M ARR. In his most recent role he was a Group Vice President of Sales managing a 140 person team that generated $100M+ in revenue.

“I joined Fauna because I recognized the company’s potential to be a major force in data management and app development via a developer focused go to market,” said Slagle. “Customers today love the developer experience and zero database operations that Fauna delivers and I am excited to join the team and help accelerate the focus on customer success.”

About Fauna

Fauna is the data API for modern applications. With Fauna, developers can simplify code, reduce costs, and ship applications faster by replacing their database infrastructure with a highly productive and programmable data API that combines the power of custom business logic with the ease of GraphQL. The underlying globally distributed storage and compute engine is fast, consistent, and reliable, with a modern security infrastructure. Itself a serverless offering, Fauna is quick to get started with and lets developers experience freedom from database operations at any scale. Innovators like Hannon Hill, ShiftX, DigitalAX, and MeetKai trust Fauna to power their applications. Backed by premier venture investors Madrona Venture Group, ADDITION, GV, and CRV, Fauna is headquartered in San Francisco with an experienced leadership team hailing from Microsoft, Okta, Amazon, New Relic, Twitter and Oracle. For more information visit fauna.com or follow us at @fauna.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye